"Medical Fast Reading Society" Oxford University launches phase 2/3 clinical trial of new coronavirus candidate vaccine

Hebei Health and Health Commission issued a letter: "Four-medical linkage" comprehensive drug control costs, Kexing Zhongwei Bio was invested 15 million U.Sdollars for further development of the new coronavirus vaccine, the number of pediatrics, otolaryngology patients in Japan continued to decline, the European Union accelerated review of the 100-time Meishi Guibao and Bluebird bioCAR-T therapy ..On the 25th, the Shanghai Municipal Committee and the Shanghai Municipal People's Government issued the Implementation Opinions on Promoting the Innovation and Development of Chinese Medicine Heritage, which put forward new measures to further accelerate the development of Chinese medicine from seven aspects, such as optimizing the service system of Chinese medicine, exerting the unique role of Chinese medicine in health services, developing the Chinese medicine industry, strengthening the construction of chinese medicine personnel, promoting the inheritance and innovation of Chinese medicine, and reforming and improving the mechanism of Chinese medicine management(Shanghai Municipal Committee)recently, Hebei Province Health and Health Commission issued a notice, put forward medical, medical, medical, medical prices, "four medical linkage", through the comprehensive deepening of centralized procurement and use of drugs and linkage reform, strict drug purchase and sale tax management, the launch of DRG actual payment in 2021, strengthen the monitoring of key drugs, strengthen drug price monitoring and other policy measures to control feesUnlike the "three-doctor linkage" of medical insurance, medicine and medical treatment, Hebei's creative addition of "medical price" putforward the four-doctor linkage, which deserves attention(Hebei Provincial Health and Health Commission)days ago, Cixi City, Zhejiang Province, the new crown pneumonia outbreak prevention and control work leading group issued "on the further do a good job of the city's new crown pneumonia outbreak normalprevention and control work notice" (Chiantifa (2020) No21), to open up the retail drugstore selling related to fever, cough and other 263 kinds of drug sales restrictions(21st Century Pharmacy)Kexing Holding Biotechnology Co., Ltdannounced that its subsidiary Beijing Kexing Zhongwei Biotechnology Co., Ltdhas received a $15 million investment from Shangyi Capital and Vivien Capital for further development of the new coronavirus inactivated vaccine CoronaVacThe two investors each provided $7.5 million in convertible bonds, and investors could choose to convert them to interest-bearing loans or 7.5 per cent of CST's total equityTheJapan Institute of Medical Information recently released the latest prescription data, in April pediatric patients decreased by 42% compared to the same period last year, otolaryngology decreased by 43% compared to the same period last year, mainly because the "Declaration of Emergency" issued, the Japanese people also entered the "Stay Home" mode, self-restraint to reduce the number of patients infected with new coronary pneumonia, so the number of patients decreased significantly(Pharmaceutical representative) 25, the State Administration of Market Supervision and Administration announced the latest batch of special medical use formula food approved list, Abao Pharmaceuticals independently developed the unique medical use of all-nutrition formula powder approved (Sina Pharmaceutical News) recently, the evaluation of Nektar Therapeutics pilot immuno-oncology candidate drug bempegdesleukin (NKTR-214) and The Persimmon Squibb PD-1 therapy Opdivo (niumvolab, Navuliyu monoantigen) in the American Cancer Society Cancer Research Journal (Sina Pharmaceutical News) Time Meishi Guibao and partner Bluebird Bio recently jointly announced that the European Medicines Agency has accepted the idecabtagene vicleucel (ide-cel, bb2121) marketing authorization application ide-cel is a research B-cell mature antigen (anti-BCMA)-oriented chimeric antigen receptor (CAR) T-cell therapy developed for treatment of patients with recurrent/incurable multiple myeloma (R/R MM) (Bio Valley) recently, Regenerative Yuan and Sanofi announced positive results from a key Phase 3 clinical Part A in patients 12 years of age and older with eosinophilic granulocyte The trial reached the primary common endpoint and all major minor endpoints, and Dupixent was the first and only biological agent to show positive and clinically significant results in the patient population Part B of the Phase 3 trial is evaluating an additional Dupixent administration regimen (Sina Pharmaceutical News) Bayer announced a commercial cooperation agreement with WaveForm Combining WaveForm's innovative know-how and Bayer's extensive experience and expertise in diabetes management, this partnership will bring innovative dynamic blood glucose monitoring solutions to Chinese patients and doctors , Oxford University announced that it will work with partners to launch phase 2/3 clinical trials of its new coronavirus candidate vaccine The press release noted that the phase 1 clinical study of the vaccine candidate began in April and that more than 1,000 healthy volunteers have been vaccinated and their follow-up is under way (Pharmaceutical Mingkant)